
Ambu is powering ahead in its Q1. For the first time, the pharmaceutical firm's revenue has reached the DKK 1bn (USD 163.3m) mark early in the year.
All in all, Ambu has had a revenue of DKK 1,013m in the first three months of the company's staggered fiscal year. This greatly surpasses the DKK 760m which the firm scraped together in the same time period in the last financial year.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app